12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Biosimilar etanercept: Phase III started

Novartis' Sandoz generics unit began an international Phase III trial to compare biosimilar etanercept vs. Enbrel etanercept. Sandoz said data from the trial are expected to support regulatory applications for the biosimilar in the U.S. and EU. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) and Pfizer Inc. (NYSE:PFE, New York, N.Y.) co-market Enbrel in the U.S. and Canada, while...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >